Objective
The Critical Illness Stress-Induced Immune Suppression (CRISIS) Prevention Trial was a randomized, masked trial of zinc, selenium, glutamine and metoclopramide compared to whey protein in delaying nosocomial infection in pediatric intensive care unit (PICU) patients. One fourth of study subjects were diagnosed with nosocomial lower respiratory infection (LRI), which contributed to subjects receiving antibiotics 74% of all patient days in the PICU. We analyzed diagnostic and treatment variability among the participating institutions and compared outcomes between nosocomial LRI subjects (n=74) and intubated subjects without nosocomial infection (n=155).
Design
Post-hoc analysis
Setting
Eight hospitals in the Collaborative Pediatric Critical Care Research Network
Patients
CRISIS study subjects.
Interventions
None
Measurements and Main Results
Variability across institutions existed in the frequency and manner by which respiratory secretion cultures were obtained, processed and results reported. Most results were reported semi-quantitatively and both Gram stains and antibiotic sensitivities were frequently omitted. The nosocomial LRI diagnosis was associated with increased PICU lengths of stay compared to those who were intubated without nosocomial infection (24±19 vs 9±6 days; p<0.001) and antibiotic use (38±29 vs. 15±20 antibiotics days; p<0.001). Despite antibiotic treatment, the same bacteria persisted in 45% of follow-up cultures.
Conclusions
The CRISIS data demonstrate that the nosocomial LRI diagnosis is associated with longer lengths of stay and increased antibiotic use, but there is considerable diagnostic and treatment variability across institutions. More rigorous standards for when and how respiratory cultures are obtained, processed, and reported are necessary. Bacterial persistence also complicates the interpretation of follow-up cultures.